Latest Annexon Biosciences News & Updates

See the latest news and media coverage for Annexon Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Annexon Biosciences

Developer of C1q inhibitors for complement-driven diseases

annexonbio.com

Headquarters: South San Francisco, United States
Founded year: 2011
Company type: Public company
Number of employees: 100–200

Last updated Today

Latest news about Annexon Biosciences

In short: Annexon Biosciences progressed its clinical pipeline for Guillain-Barré syndrome and geographic atrophy while securing funding into 2027.

Company announcements

May 7 Annexon Biosciences

Annexon reports Q1 2026 financial results

Cash at $225M extends runway to H2 2027. Portfolio updates include Phase 3 GA data in Q4 2026, GBS BLA in 2026, ANX1502 POC in 2026.

April 21 Annexon Biosciences

Annexon presents Phase 3 results at AAN Meeting

Henk-André Kroon presents data on tanruprubart for Guillain-Barré syndrome in Chicago. GBS is a rapid-onset neuromuscular emergency with unmet needs.

March 30 Annexon Biosciences

Annexon reports Q4 and year-end 2025 financial results

Highlights portfolio progress including ARCHER II data expected Q4 2026, tanruprubart MAA filed, $238.3M cash runway to H2 2027. Net loss $48.3M for Q4, $208.5M for year.

January 12 Annexon Biosciences

Annexon highlights 2026 milestones for immunotherapies

Tanruprubart MAA filed for GBS; vonaprument Phase 3 data for GA expected H2 2026; ANX1502 POC data anticipated. Funds into 2027.

Media coverage

Yesterday NeurologyLive

Complement-Targeting Agent ANX005 Demonstrates Therapeutic Efficacy in Phase 3 Study of Guillain-Barré Syndrome | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Data from a phase 3, double-blind, placebo-controlled study (NCT04701164) revealed that a single dose of investigational ANX005 (Annexon Biosciences) at 30 mg/kg doses led to...

June 4 Yahoo Finance

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates acros...

May 7 Markets Insider

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision...

April 19 The Globe and Mail

Cyber Risks Threaten Annexon Biosciences' Clinical Operations, Reputation and Financial Health

Annexon Biosciences, Inc. faces growing exposure to cyber threats across its own and third-party IT environments, despite existing safeguards and monitoring efforts. A successful attack...

Never miss news about Annexon Biosciences

Track Annexon Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.